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Prevalence of qacA/B Genes and Mupirocin Resistance Among
Methicillin-Resistant Staphylococcus aureus (MRSA) Isolates in the
Setting of Chlorhexidine Bathing Without Mupirocin
David K. Warren, MD, MPH;1 Martin Prager, MD;1 Satish Munigala, MBBS, MPH;1 Meghan A. Wallace, BS;2
Colleen R. Kennedy;2 Kerry M. Bommarito, PhD;1 John E. Mazuski, MD, PhD;3 Carey-Ann D. Burnham, PhD2

objective. We aimed to determine the frequency of qacA/B chlorhexidine tolerance genes and high-level mupirocin resistance among
MRSA isolates before and after the introduction of a chlorhexidine (CHG) daily bathing intervention in a surgical intensive care unit (SICU).
design.
setting.
patients.

Retrospective cohort study (2005–2012).
A large tertiary-care center.
Patients admitted to SICU who had MRSA surveillance cultures of the anterior nares.

methods. A random sample of banked MRSA anterior nares isolates recovered during (2005) and after (2006–2012) implementation of a
daily CHG bathing protocol was examined for qacA/B genes and high-level mupirocin resistance. Staphylococcal cassette chromosome mec
(SCCmec) typing was also performed.
results. Of the 504 randomly selected isolates (63 per year), 36 (7.1%) were qacA/B positive ( + ) and 35 (6.9%) were mupirocin resistant.
Of these, 184 (36.5%) isolates were SCCmec type IV. There was a signiﬁcant trend for increasing qacA/B (P = .02; highest prevalence, 16.9% in
2009 and 2010) and SCCmec type IV (P < .001; highest prevalence, 52.4% in 2012) during the study period. qacA/B( + ) MRSA isolates were
more likely to be mupirocin resistant (9 of 36 [25%] qacA/B( + ) vs 26 of 468 [5.6%] qacA/B( − ); P = .003).
conclusions. A long-term, daily CHG bathing protocol was associated with a change in the frequency of qacA/B genes in MRSA isolates
recovered from the anterior nares over an 8-year period. This change in the frequency of qacA/B genes is most likely due to patients in those years
being exposed in prior admissions. Future studies need to further evaluate the implications of universal CHG daily bathing on MRSA qacA/B
genes among hospitalized patients.
Infect Control Hosp Epidemiol 20 16 ; 37 :5 9 0– 5 97

Methicillin-resistant Staphylococcus aureus (MRSA) is a major
cause of healthcare-associated infections.1–3 Compared with
methicillin-susceptible strains, MRSA is associated with
increased risk of adverse health outcomes and increased
treatment costs.4,5 Multiple studies have shown that MRSA
nasal colonization is a risk factor for subsequent MRSA
infection.6–8 Interventions to interrupt MRSA transmission
among hospitalized patients include active surveillance for
colonization and contact precautions.9,10
Recently, the use of chlorhexidine (CHG)-based body wash,
either alone or in combination with intranasal antibiotics such
as mupirocin, has been demonstrated to reduce the incidence
of MRSA transmission and subsequent infection among
hospitalized patients.11–13 However, widespread use of

chlorhexidine may result in the selection of bacteria that are
chlorhexidine tolerant, with the potential to limit the
effectiveness of this intervention in the future. In S. aureus,
chlorhexidine tolerance is associated with the qac gene family
(qacA/B), which code for efﬂux pumps capable of extruding
chlorhexidine and other biocidal compounds from the
cell.14–17 The presence of qacA/B has been associated with
elevated minimum bactericidal concentrations for chlorhexidine and MRSA decolonization protocol failures.18,19 The
implementation of a daily topical chlorhexidine antiseptic
protocol among ICU patients resulted in the selection of a
qacA/B–positive ( + ) MRSA strain, while the transmission of
other MRSA strains was reduced during the 2-year period.20
Some plasmids harboring the qac genes may contain additional
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antibiotic resistance genes.14,17,21 In vitro evidence that CHG
may induce selective pressure in clinical MRSA isolates18,20
highlights the importance of antiseptic tolerance evaluation as
part of infection control practices.
Mupirocin, a topical antibiotic, is widely used for treatment
of uncomplicated skin and soft-tissue infections and MRSA
decolonization. Resistance to mupirocin is broadly classiﬁed as
low-level resistance (typically deﬁned as having a minimum
inhibitory concentration [MIC] of 8–256 mg/L), and highlevel resistance (MIC ≥ 512 mg/L)18,20,22,23 is most commonly
conferred by the plasmid-borne mupA gene, although other
mechanisms have been reported.24–26 Mupirocin resistance
has been associated with reduced effectiveness of decolonization strategies.27 Its prevalence is variable, ranging from 4%
among MRSA isolates in Canadian hospitals to as much as
80% in a Swiss hospital in the context of widespread
mupirocin use.28,29
Based upon studies of chlorhexidine-based daily bathing
protocols and subsequent MRSA infection, this practice is
becoming more widespread in hospitals. However, the longterm effects of daily chlorhexidine bathing on the prevalence of
qacA/B resistance genes in MRSA isolates in the hospital
setting is unknown.
The objective of this study was to determine changes in the
frequency of qacA/B gene carriage and mupA-mediated
high-level mupirocin resistance among nasal MRSA isolates
recovered from active surveillance nasal cultures in the 8-year
period during and following implementation of a universal
chlorhexidine bathing intervention in a surgical intensive care
unit (SICU).

m e th o d s
Study Design and Setting
We conducted a retrospective cohort study of patients admitted between 2005 and 2012 to the 24-bed surgical intensive
care unit of Barnes-Jewish Hospital (BJC), a 1,250-bed
tertiary-care hospital in St. Louis, Missouri.
Chlorhexidine Bathing Intervention
On June 1, 2005, the SICU implemented a daily chlorhexidine
bathing protocol, replacing a once-daily bath with nonmedicated soap and water. Daily water basin baths used 4%
chlorhexidine gluconate soap (Exidine, Cardinal Health,
McGraw Park, IL). Compliance, as measured by number of
soap bottles used per patient day, was >90%. Chlorhexidine
soap was diluted in water to achieve a ﬁnal concentration of
approximately 0.125% (1,250 µg/mL). There was no routine
use of intranasal mupirocin during this time period.
Data Collection
All patients admitted to the SICU had a swab of the anterior
nares obtained for MRSA surveillance cultures per the hospital
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infection prevention policy. Patients who stayed for >2 days
had nasal swabs weekly and at SICU discharge. All MRSA
isolates were saved from 2005 to 2012. For this study, isolates
from patients admitted to the SICU in 2005 were considered to
be collected in the implementation period, and the
post-implementation period was 2006–2012.
We estimated a MRSA qacA/B baseline prevalence of 1%,
based upon a study of household prevalence in the Saint Louis
community.30 Thus, we estimated that 63 randomly selected
isolates per year (504 total) would be required to detect a 1%
per year increase in prevalence of qacA/B positivity during the
study period (β = 0.80 and α = 0.05). Random sampling was
done by computer analysis using SPSS version 20 (IBM SPSS,
Chicago, IL).
Patient demographics, length of stay in days (LOS, median
[interquartile range, IQR]), previous hospitalization history,
presence of comorbidities and other characteristics were
obtained from the Barnes-Jewish Hospital (BJC) medical
informatics database for all patients whose isolates were
included in this study. Patients with negative admission
cultures but subsequently had a positive nasal MRSA culture
during the SICU admission were considered to have
ICU-acquired MRSA.
Microbiological Methods
MRSA culture testing was performed as described
previously.31 Isolates were stored in skim milk at −70°C prior
to analysis. Selected isolates were subcultured on sheep’s blood
agar. MRSA was conﬁrmed using cefoxitin disk diffusion
testing according to CLSI standards.32 Selected samples
underwent ampliﬁcation14 of the qacA/B genes using a
polymerase chain reaction (PCR) with the following primers:
F: 5'-CTA TGG CAA TAG GAG ATA TGG TGT-3',
R: 5'-CCA CTA CAG ATT CTT CAG CTA CAT G-3'. As a
conﬁrmatory test, a second set of qacA/B PCR was performed
on all initially positive isolates.30
We performed mupirocin phenotypic susceptibility testing
by Kirby-Bauer disk diffusion using a 200-µg mupirocin disk
(Oxoid, Hampshire, UK) on Mueller-Hinton agar (Hardy
Diagnostics, Santa Maria, CA).23 Isolates with no zone of
inhibition around the mupirocin disk were classiﬁed as
mupirocin resistant. All mupirocin-resistant isolates underwent PCR ampliﬁcation for detection of mupA30,32,33 using the
following primers: F: 5'-TAT ATT ATG CGA TGG AAG GTT
GG-3', R: AAT AAA ATC AGC TGG AAA GTG TTG-3'. All
MRSA isolates underwent SCCmec typing using a multiplex
PCR that could detect and resolve SCCmec types I through V.34
Statistical Analysis
The Cochran–Armitage trend test was used to compare qacA/B
and SCCmec type frequencies by year. Statistical signiﬁcance
was tested using the Mantel-Hansel χ2 test, univariate logistic
regression, Student t test, or Wilcoxon signed rank test as
appropriate. A 2-sided P ≤ .05 was considered signiﬁcant.
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Statistical analyses were performed with SPSS and SAS v9.3
(SAS Institute, Cary, NC).
This study was approved by the Washington University
Human Research Protection Ofﬁce.

results

from another hospital or facility (11 [30.5%] qacA/B( + ) vs
91 [19.5%] qacA/B( − ); P = .13). Compared with patients
colonized with qacA/B( − ) MRSA isolates, patients colonized
with qacA/B( + ) MRSA isolates were less likely to have diabetes
(5.6% vs 22.3%; P = .02) or congestive heart failure
(0 vs 13.7%; P = .009) (Table 2).

Patient Characteristics
Overall, 1,880 banked MRSA isolates recovered from the
anterior nares from 2005 to 2012 were available for testing. In
total, 41 isolates were excluded: 27 were repeat isolates from
the same patient, 13 were methicillin-susceptible S. aureus on
conﬁrmatory testing, and 1 was from a patient who was not in
the SICU at the time of testing (Figure 1). After exclusions,
MRSA isolates from 504 randomly selected patients (63 per
year) were included in the study (Figure 1). Characteristics of
the study participants are shown in Table 1. Notably, 70%
of the MRSA isolates were obtained within the ﬁrst 2 days of
SICU admission. Among all the MRSA isolates, 36 (7.1%) were
qacA/B( + ). There was no signiﬁcant difference in the prevalence of qacA/B MRSA isolates among patients in whom
MRSA was initially recovered >2 days after ICU admission
(10 [27.8%] qacA/B( + ) vs 144 [30.8%] qacA/B( − ); P = .85).
Also, we found no signiﬁcant difference in the prevalence of
qacA/B positivity among MRSA isolates relative to transfer

Prevalence of qacA/B( + ) and mupA( + )
The prevalence of qacA/B( + ) MRSA isolates was 6.2% in the
implementation year, then this rate fell to 0–1.5% between
2006 and 2008. The prevalence then increased to 16.9% for
2 years (2009 and 2010) and subsided thereafter, indicating a
signiﬁcant trend for qacA/B (P = .02) (Figure 2). Of the MRSA
isolates tested, 35 (6.9%) were mupirocin resistant by the
diffusion disk method. All of the phenotypically mupirocinresistant isolates were mupA( + ).
The prevalence qacA/B( + ) isolates obtained <2 days
showed a signiﬁcant trend compared with isolates obtained
≥ 2 days of SICU admission (P = .04 for qacA/B <2 days after

table 1.

Patient Characteristics

Patient Characteristic
Age, y, median (IQR)
Female gender
Race
White
Non-white
Medical comorbidities
CHF
COPD
Diabetes mellitus
Malignancy
Cirrhosis
Solid organ transplant
ESRD
HIV infection
Previous admissions to BJH in prior 12 months
0
1–5
>5
Central venous catheter in place
Days from ICU admission to MRSA (+ ) culture
1–2 d
>2 d
Outcomes
ICU LOS, d, median (IQR)
Hospital LOS, d, median (IQR)
In-hospital mortality
NOTE.

ﬁgure 1. Selection of study population. MRSA, methicillinresistant S. aureus; MSSA, methicillin-susceptible S. aureus; SICU,
surgical intensive care unit.

No. (%) (N = 504)
63 (48–75)
207 (42)
375 (74.4)
129 (25.6)
64 (12.7)
107 (21.2)
106 (21)
79 (15.7)
19 (3.8)
6 (1.2)
9 (1.8)
4 (0.8)
167 (33)
201 (40)
136 (27)
151 (30)
350 (70)
154 (30)
3 (2–9)
14 (7–26)
78 (15.5)

IQR, interquartile range; MRSA, methicillin-resistant S. aureus;
CHF, congestive heart failure; COPD, chronic obstructive pulmonary
disease; ERSD, end-stage renal disease; HIV, human immunodeﬁciency
virus; BJH, Barnes-Jewish Hospital; ICU, intensive care unit; LOS,
length of stay.

prevalence of qaca/b in mrsa in an icu

table 2. Comparison of Study Participants with MRSA
Intranasal Isolates by qacA/B Status
qacA/B(− )
qacA/B(+ )
MRSA, No.
P
MRSA, No.
(%) (n = 36) (%) (n = 468) Value
Age, y, median (IQR)
Female gender
Race
White
Non-white
Medical comorbidities
CHF
COPD
Diabetes mellitus
Malignancy
Cirrhosis
Solid organ transplant
ESRD
HIV infection
Previous admissions to BJH in
prior 12 moa
0
1–5
>5
Central venous catheter in
place
Days from ICU admission to
MRSA (+ ) culture
Days 1–2
>2 days
SCCmec type
Type IV
Other
Outcomes
ICU LOS, d, median (IQR)
Hospital LOS, d, median
(IQR)
In-hospital mortality
Admission referral source
Physician or ER
Other acute care hospital or
other facility
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Characteristics of qacA/B( + ) Isolates Recovered by Year
Due to the observed signiﬁcant trends, we evaluated the data
regarding admission source (ie, referred by physician, emergency room (ER), or another facility or acute care facility),
hospital LOS, LOS prior to SICU admission, and rate of
hospital admissions (previous 12 months) for patients with
qacA/B( + ) isolates obtained during 2009–2010 and compared
them with all other years. We found no signiﬁcant difference
in the admission source (16 [72.7%] vs 9 [64.3%], P = .72 for
admission by physician/ER), hospital stay prior to SICU
admission (1 [0–6] vs 0 [0–2], P = .23), or total hospital LOS
(14.5 [9–23] vs 22 [7–39], P = .11). However, compared with
qacA/B( + ) isolates from other study years, the qacA/B( + )
isolates from 2009 and 2010 were more likely to have ≥1
hospital admissions in the prior year (20 [90.9%] vs 7 [50.0%];
P = .01) (Table 4).

60 (41–71)
16 (44.4)

63 (49–75)
191 (40.8)

.24
.72

31 (86.1)
5 (13.9)

344 (73.5)
124 (26.5)

.11

0
6 (16.7)
2 (5.6)
3 (8.3)
0
0
1 (2.8)
0

64 (13.7)
101 (21.6)
104 (22.2)
76 (16.2)
19 (4.1)
6 (1.3)
8 (1.7)
4 (0.9)

.009
.67
.02
.33
.38
1.00
.48
…

11 (30.5)
21 (58.3)
4 (11.1)
11 (30.6)

156 (33.3)
180 (38.5)
132 (28.2)
140 (30)

.85
.11
.25
1.00

26 (72.2)
10 (27.8)

324 (69.2)
144 (30.8)

.85

Of the 504 MRSA isolates tested, 10 (2%) were SCCmec type I,
305 (60.5%) were SCCmec type II, 3 (0.6%) were SCCmec type
III, 184 (36.5%) were SCCmec type IV, and 2 (0.4%) were
SCCmec type V. The prevalence of MRSA isolates that were
SCCmec type IV signiﬁcantly increased from 23.8% in 2005 to
52.4% in 2012 (P < .0001). There was no signiﬁcant difference
in the prevalence of qacA/B( + ) by SCCmec type during the
study period (Table 3).

15 (41.7)
21 (58.3)

169 (35.9)
299 (64.1)

.47

d is c u s s i o n

5 (2–15)
16 (9–32)

3 (2–9)
14 (7–26)

.12
.74

2 (5.6)

76 (16.9)

.09

25 (69.5)
11 (30.5)

377 (80.5)
91 (19.5)

.13

NOTE. IQR, Interquartile range; MRSA, methicillin-resistant
S. aureus; CHF, congestive heart failure; COPD, chronic obstructive
pulmonary disease; ERSD, end-stage renal disease; HIV, human
immunodeﬁciency virus; BJH, Barnes-Jewish Hospital; ICU, intensive
care unit; LOS, length of stay; ER, emergency room.
a
Univariate logistic regression (No previous admission as a reference
group).

admission vs P = .29 for qac A/B ≥2 days after admission)
(Figure 3).
Among all isolates, 9 (1.8%) were both qacA/B( + ) and
mupA( + ). These isolates occurred in 2005 (n = 1), 2008
(n = 1), 2009 (n = 3), 2010 (n = 3), and 2012 (n = 1). MRSA
isolates that were qacA/B( + ) were more likely to be mupA( + )
than qacA/B( − ) isolates (25% vs 5.6%; P = .003) (Table 3).

Prevalence of SCCmec Types

In our 24-bed SICU, the prevalence of qacA/B genes associated
with chlorhexidine tolerance changed in MRSA nasal isolates
over the 8-year study period of daily patient bathing with
chlorhexidine soap. This change was nonlinear and was associated with an increase in prevalence in years 5 and 6 of the
study, then decreased in the remaining 2 years. A comparison
of study patients from 2009 and 2010 versus patients from
other study years revealed no signiﬁcant difference in ICU and
hospital LOS or rates of hospital admission in the prior
12 months. However, patients from these 2 years were more
likely to have a MRSA isolate cultured from a nasal swab collected within the ﬁrst 2 days of ICU admission (95 of
126 [75.4%] vs 247 of 378 [66.9%]; P = .04). Our comparison
of qacA/B( + ) isolates from 2009 and 2010 with qacA/B( + )
isolates from other study years also revealed no signiﬁcant
difference in admission source, hospital LOS and LOS prior to
SICU admission; however, qacA/B( + ) isolates from 2009 and
2010 were more likely to have ≥1 hospital admissions in the
prior year, suggesting a possibility of an expansion of qacA/B
( + ) MRSA at BJH during this time period, which resulted in
qacA/B( + ) patients in those years being exposed in prior
admissions. Daily CHG bathing was implemented in 2009 in
the other 5 hospital ICUs but not on other inpatient units.
There was no marked change in the prevalence of MRSA
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ﬁgure 2.
p, P value.
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Prevalence of qacA/B( + ) among sampled MRSA nasal isolates, per year (2005–2012). MRSA, methicillin-resistant S. aureus;

ﬁgure 3. Annual prevalence of qacA/B(+ ) MRSA, stratiﬁed by detection <2 days (n = 24) versus ≥2 days (n = 12) after ICU admission.
MRSA, methicillin-resistant S. aureus; p, P value.

table 3. Comparison of MRSA Isolate Characteristics by
qacA/B Status

mupA(+ )
mupA( − )
SCCmec type
I
II
III
IV
V

qacA/B( + ) MRSA,
No. (%) (n = 36)

qacA/B(− ) MRSA,
No. (%) (n = 468)

9 (25)
27 (75)

26 (5.6)
442 (94.4)

.003

2 (5.5)
18 (50.0)
0
15 (41.7)
1 (2.8)

8 (1.7)
287 (61.4)
3 (0.6)
169 (36.1)
1 (0.2)

.15
.21
.00
.59
.13

P Value

NOTE. MRSA, methicillin-resistant S. aureus; SCCmec, staphylococcal
cassette chromosome mec.

isolates containing any of the SCCmec type’s genetic element in
these 2 years that would suggest a clonal MRSA outbreak in the
ICU. We cannot rule out the possibility of dissemination of

qacA/B due to horizontal transmission of a qacA/B-containing
plasmid among the endemic MRSA strains in the unit.35
However, the prevalence of this genetic element did not
remain persistently elevated in the setting of stable daily
chlorhexidine use throughout the post-implementation period. Our ﬁndings suggest that long-term daily chlorhexidine
bathing at the concentration used in this ICU did not result in
sustained, widespread dissemination of genes encoding for
chlorhexidine tolerance.
The prevalence of high-level phenotypic mupirocin resistance among MRSA nasal isolates was 6.9% and remained
stable. This ﬁnding is similar to that of an earlier study of nasal
MRSA isolates from patients in this ICU from 2002 to 2004,
which reported the high-level mupirocin resistance rate to be
8.6%.29 Intranasal mupirocin therapy was not systematically
used in any area of the hospital during the study period. All
high-level mupirocin-resistant MRSA isolates we tested contained mupA. Among the MRSA isolates tested, 9 (1.8%)

prevalence of qaca/b in mrsa in an icu

table 4.
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Comparison of qacA/B( + ) Isolates by Year

Admission referral source
Physician or ER
Other acute care hospital or other facility
Previous admissions
None
>1 previous admission
Length of Stay in days (median, IQR)
Hospital
SICU
Prior to SICU admission

qacA/B( + ) MRSA
(2009, 2010), No. (%)
(n = 22)

qacA/B( + ) MRSA, All Other
Years, No. (%)
(n = 14)

16 (72.7)
6 (27.3)

9 (64.3)
5 (35.7)

.72

2 (9.1)
20 (90.9)

7 (50.0)
7 (50.0)

.01

14.5 (9–23)
5 (2–12)
1 (0–6)

22 (7–39)
5 (2–27)
0 (0–2)

.31
.62
.23

contained both chlorhexidine and mupirocin resistance
determinants. This prevalence is similar to that reported in a
study of community-dwelling individuals in St. Louis,
Missouri, with a history of skin and soft-tissue infections in
which 8 of 755 (1.1%) of MRSA isolates tested contained both
resistance elements.30 Further study is needed to determine
whether the use of universal decolonization regimens using
both chlorhexidine and mupirocin11 leads to selection for
these dually resistant strains in ICU patients.
The SCCmec type IV mobile genetic element has been
associated with community-associated MRSA strains in the
United States and elsewhere,36 whereas isolates with SCCmec
type II have classically been hospital-associated strains. The
proportion of MRSA nasal isolates containing the SCCmec type
IV mobile genetic element increased steadily over the 8-year
study period. This ﬁnding is consistent with results from other
healthcare facilities,37,38 suggesting a shift in epidemiology and
that community-associated MRSA strains are now widely
disseminated in healthcare facilities.
The present study has limitations inherent to its
retrospective design and the use of patient isolates from a
single-center site. We were unable to test all the MRSA isolates
collected during the study period due to limited resources.
However, our random sampling methodology generated a
sample with adequate power (β = 0.8), which was representative of the patient population admitted during the study
period. All of the isolates evaluated in this study were
recovered from the anterior nares; thus, we do not know the
prevalence of qacA/B in MRSA isolates recovered from other
body sites. We did not evaluate phenotypic tolerance to
chlorhexidine; therefore, we may have underestimated less
common mechanisms of chlorhexidine tolerance.39,40 In
addition, we do not know the MIC or minimal bactericidal
concentration (MBC) of the strains in this study possessing
qacA/B. Chlorhexidine tolerance among Gram-negative
bacteria was not examined in our study. Our study was
performed in a single ICU; thus, generalizability of results to
other facilities may be limited.

P
Value

Our study has several strengths, including a long follow-up
period to evaluate the prevalence rate, the use of both phenotypic and genotypic methods to assess mupirocin resistance, a
standardized surveillance protocol for collection of MRSA
nasal isolates, and a well-established chlorhexidine bathing
program in the ICU.
In conclusion, prevalence of qacA/B associated with chlorhexidine tolerance did change over time among colonizing
MRSA isolates over the 8-year period of daily patient bathing
with chlorhexidine soap; however, this was not a linear relationship. This change in the frequency of qacA/B genes is most
likely due to patients in those years being exposed in prior
admissions. The prevalence of MRSA with SCCmec type IV
increased over the study period. Further studies are needed to
determine whether other ICU-based decolonization strategies,
such as universal treatment with chlorhexidine and intranasal
mupirocin, will result in selection of co-resistant isolates.
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